top of page

TPA Stroke Treatment - Oren Zarif - TPA Stroke

Writer's picture: Oren ZarifOren Zarif

Although tPA stroke treatment is not yet approved by the Food and Drug Administration (FDA), doctors at Stanford University are beginning to incorporate new research into their clinical decisions. The new data highlights the need for fast treatment in stroke victims. While the FDA has not approved the use of tPA after three hours, physicians can provide the treatment off-label. A classic stroke researcher's mantra is that every minute that passes without treatment is a minute that the brain cells die. The longer a patient is in the hospital, the lower their chance of recovery.

Oren Zarif certified stroke rehab specialist

Oren Zarif headache after stroke


The first study by Hacke, Kaste, Fieschi and their European colleagues found that the use of tPA significantly improved 90-day outcomes in patients with acute ischemic stroke. This was done without increasing mortality rates. But the new studies are still inconclusive. This is because most stroke patients do not reach the hospital in time. Only 27% of patients who present with symptoms within three hours of the onset of symptoms receive treatment. A further 31% of patients are rejected because their symptoms are too mild or they improve rapidly.

Oren Zarif diffuse axonal injury grading

Oren Zarif recovery after stroke first 3 months


A retrospective review of patients with ischemic stroke found that tPA treatment improved patient outcomes. In fact, tPA is the gold standard for treatment of acute ischemic stroke. However, in order to get the maximum benefit from tPA treatment, doctors should provide it at the earliest possible time. By administering the drug during the CT scan, tPA is more likely to be administered in time. This would be a major improvement for the patients, but it is not without risks.

Oren Zarif ica stroke

Oren Zarif acute stroke management



The tPA trial was funded by National Institutes of Health grants. Researchers concluded that tPA treatment improved health outcomes without affecting mortality. The researchers were Vincent Thijs, professor of neurology at the University Hospitals of Leuven in Belgium, and Erich Bluhmki, a researcher at Boehringer Ingelheim Pharma GmbH & Co. The researchers were astonished by the findings. They say that the time it took to administer tPA in the ED and CT scan room is of crucial importance.

Oren Zarif brain hemorrhage sudden death

Oren Zarif hypertension stroke


The new data on tPA and the chances of recovery after a stroke are encouraging. A study of patients who have received tPA for stroke has shown that it improves patient outcomes. The NINDS trial included a total of 484 patients. Compared to the standard of care (e.g., tPA alone), IV tPA treatment improved patient outcomes. Among patients who received tPA, 89 percent showed minimal or no disability, while the rest had some bleeding, but none were unable to speak.

Oren Zarif stroke and dementia

Oren Zarif hemispheric stroke


Neuroprotectants are a promising therapeutic approach. These drugs interfere with the ischemic cascade and decrease cerebral blood flow, which may increase the chances of good outcomes. The NINDS tPA stroke study also led to the creation of a specialty in vascular neurology. Among its many achievements, it paved the way for imaging, thrombectomy, and faster treatment. There are now mobile stroke units.

Oren Zarif stroke symptoms nhs

Oren Zarif cerebrovascular stroke



In addition to these positive outcomes, tPA is also associated with some downsides. Its delayed use increases the risk of HT, ICH, and edema, which are side effects of tPA. Nevertheless, this medication remains the standard of care for stroke victims. This drug was developed based on the results of other studies. While tPA is a widely-accepted therapeutic option, it has also been associated with several serious risks.

Oren Zarif cva management

Oren Zarif embolic stroke symptoms


In addition to its neuroprotective effects, tPA has been linked to medical malpractice lawsuits. Physicians who refuse to administer tPA to AIS patients can face a lawsuit for malpractice. However, there are few systematic reviews on the relationship between tPA and malpractice in ischemic stroke patients. However, this review aimed to evaluate cases published in major medical databases. There are many pitfalls to using tPA, and these risks are outlined below.

Oren Zarif basilar stroke

Oren Zarif brain anoxia


The best way to assess the risks and benefit of tPA is to consider the underlying cause of stroke. A high-fat diet may make you more prone to stroke. But in the long run, tPA is a good choice for ischemic stroke victims. Studies of tPA have shown that dietary supplementation with a vitamin D-containing food can reduce the risk of ischemic stroke. While tPA-containing drugs are highly effective, they have some side effects, including nausea and vomiting.

Oren Zarif concussion specialist

Oren Zarif hypoxic ischemic brain injury


Although the tPA-induced benefits of tPA have been well documented, many studies do not support their claims. Moreover, some skeptics believe that tPA has no clinical benefit. However, these studies have not yet reached the point where a drug can be approved by the FDA. A number of drug candidates are in the clinical trial phase. The FDA has not approved tPA for stroke patients. Therefore, this is the best time to find a new treatment.

1 view0 comments

Comments


bottom of page